Oncotarget

Reviews:

IκBζ: an emerging player in cancer

Marie Willems, Nadège Dubois, Lucia Musumeci, Vincent Bours and Pierre A. Robe _

PDF  |  HTML  |  Order a Reprint

Oncotarget. 2016; 7:66310-66322. https://doi.org/10.18632/oncotarget.11624

Metrics: PDF 682 views  |   HTML 1171 views  |   ?  


Abstract

Marie Willems1, Nadège Dubois1, Lucia Musumeci1, Vincent Bours1 and Pierre A. Robe1,2

1 Department of Human Genetics and GIGA Research Center, University of Liège, Liege, Belgium

2 Department of Neurology and Neurosurgery, T&P Bohnenn Laboratory for Neuro-Oncology, Brain Center Rudolf Magnus, University Medical Center of Utrecht, Heidelberglaan, Utrecht, The Netherlands

Correspondence to:

Pierre A. Robe, email:

Keywords: IκBζ, nuclear IκB protein, NF-κB pathway, cancer, perspectives

Received: January 19, 2016 Accepted: August 23, 2016 Published: August 26, 2016

Abstract

IκBζ, an atypical member of the nuclear IκB family of proteins, is expressed at low levels in most resting cells, but is induced upon stimulation of Toll-like/IL-1 receptors through an IRAK1/IRAK4/NFκB-dependent pathway. Like its homolog Bcl3, IκBζ can regulate the transcription of a set of inflamatory genes through its association with the p50 or p52 subunits of NF-κB. Long studied as a key component of the immune response, IκBζ emerges as an important regulator of inflammation, cell proliferation and survival. As a result, growing evidence support the role of this transcription factor in the pathogenesis number of human hematological and solid malignancies.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 11624